MORRISTOWN, NJ, (September 17, 2018) BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired Pneumonia (CAP) in Australasia.* The clinical-stage company is focused on a novel approach to address infectious, inflammatory and degenerative diseases through a portfolio built around rhu-pGSN technology. Separately, the company announced that it has closed a $4.1 million equity round.

Read the full press release here: Bioaegis-Therapeutics-Enrolls-Patients-Final

MORRISTOWN, NJ (BIOAEGIS THERAPEUTICS) June 19, 2018.  BioAegis Therapeutics Inc., a clinical-stage company focused on developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around recombinant plasma gelsolin (rhu-pGSN) technology presented data at ASM-Microbe 2018 demonstrating that low admission plasma gelsolin concentrations can help identify community-acquired pneumonia (CAP) patients at high risk for severe adverse outcomes.

Read the full press release here: ASM Microbe Abstract Presentation


New Patents Issued Across Multiple Geographies in US, Europe and Japan

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2017) BioAegis Therapeutics announces that during 2017 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in inflammatory disease, neurological disease and renal failure in the United States, Europe and Japan. The plasma gelsolin portfolio now includes 26 issued patents and many pending applications.

The recent review article, “Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus” in the November 15, 2017 Clinical Infectious Diseases, addresses the trends and current status of the etiology of Community Acquired Pneumonia (CAP). These data support the need for a pathogen-agnostic/host-based approach to the disease, such as BioAegis’ plasma gelsolin program. Three of the most recent studies, including the CDC’s EPIC Study published in July 2015 New England Journal of Medicine, underscore the failure to identify a causative pathogen in greater than 50% of the cases. Streptococcus pneumoniae remains the most commonly identified pathogen, although it is demonstrated in

MORRISTOWN, NJ and BOSTON, MA, (BIOAEGIS THERAPEUTICS) October 18, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate immunity, announced that data demonstrating that “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” was presented during ID Week, on October 4-8, 2017 in San Diego, California. 

ID Week is the annual meeting sponsored by the IDSA, PIDSA, HIVMA & SHEA, organizations which represent infectious disease physicians and health care professionals.

Read the full press release here: BioAegis Therapeutics ID Week Poster